DOCSLIB.ORG

N-Arachidonoyl Dopamine Modulates Acute Systemic Inflammation Via Nonhematopoietic TRPV1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

N-Arachidonoyl Dopamine Modulates Acute Systemic Inflammation via Nonhematopoietic TRPV1 This information is current as Samira K. Lawton, Fengyun Xu, Alphonso Tran, Erika of October 1, 2021. Wong, Arun Prakash, Mark Schumacher, Judith Hellman and Kevin Wilhelmsen J Immunol 2017; 199:1465-1475; Prepublished online 12 July 2017; doi: 10.4049/jimmunol.1602151 http://www.jimmunol.org/content/199/4/1465 Downloaded from Supplementary http://www.jimmunol.org/content/suppl/2017/07/12/jimmunol.160215 Material 1.DCSupplemental http://www.jimmunol.org/ References This article cites 69 articles, 11 of which you can access for free at: http://www.jimmunol.org/content/199/4/1465.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on October 1, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Author Choice Freely available online through The Journal of Immunology Author Choice option Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2017 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology N-Arachidonoyl Dopamine Modulates Acute Systemic Inflammation via Nonhematopoietic TRPV1 Samira K. Lawton,*,† Fengyun Xu,† Alphonso Tran,† Erika Wong,† Arun Prakash,† Mark Schumacher,† Judith Hellman,†,‡,1 and Kevin Wilhelmsen†,1 N-Arachidonoyl dopamine (NADA) is an endogenous lipid that potently activates the transient receptor potential vanilloid 1 (TRPV1), which mediates pain and thermosensation. NADA is also an agonist of cannabinoid receptors 1 and 2. We have reported that NADA reduces the activation of cultured human endothelial cells by LPS and TNF-a. Thus far, in vivo studies using NADA have focused on its neurologic and behavioral roles. In this article, we show that NADA potently decreases in vivo systemic inflammatory responses and levels of the coagulation intermediary plasminogen activator inhibitor 1 in three mouse models of inflammation: LPS, bacterial lipopeptide, and polymicrobial intra-abdominal sepsis. We also found that the administration of NADA increases survival in endotoxemic mice. Additionally, NADA reduces blood levels of the neuropeptide calcitonin gene- Downloaded from related peptide but increases the neuropeptide substance P in LPS-treated mice. We demonstrate that the anti-inflammatory effects of NADA are mediated by TRPV1 expressed by nonhematopoietic cells and provide data suggesting that neuronal TRPV1 may mediate NADA’s anti-inflammatory effects. These results indicate that NADA has novel TRPV1-dependent anti-inflammatory properties and suggest that the endovanilloid system might be targeted therapeutically in acute inflammation. The Journal of Immunology, 2017, 199: 1465–1475. he endogenous lipid N-arachidonoyl dopamine (NADA) (9–13). The peripheral terminals of TRPV1-expressing noci- http://www.jimmunol.org/ is composed of an arachidonic acid backbone conjugated ceptors innervate most organs and tissues. TRPV1 expressed in the T to a dopamine moiety (1). NADA is a putative endocanna- peripheral nervous system functions to integrate multiple noxious binoid and possesses activity via the G protein–coupled cannabinoid stimuli, ultimately leading to the release of neuropeptides, such as receptors (2, 3). NADA has also been classified as an endovanilloid, calcitonin gene–related peptide (CGRP) and substance P. These which is a group of endogenous activators of the transient receptor neuropeptides elicit pain and neurogenic inflammatory responses potential vanilloid 1 (TRPV1) and include the endocannabinoid (14–18). TRPV1 is also expressed in the CNS, including the spinal anandamide (AEA) and a variety of lipoxygenase products (4–6). cord, striatum, hippocampus, cerebellum, and amygdala (19–23). TRPV1, a nonselective cation channel, is primarily known for its role Finally, TRPV1 is found in nonneuronal cells, including leukocytes, by guest on October 1, 2021 in sensing pain and temperature. Of the known endovanilloids, smooth muscle cells, and endothelial cells (11, 17, 24–27). In this NADA is the most potent activator of TRPV1 and is considered to be regard, TRPV1 activation has been reported to regulate the acti- a principal endogenous TRPV1 ligand (1, 5, 7, 8). TRPV1 is also vation and proinflammatory properties of CD4+ T cells (28) activated by a variety of noxious insults, including heat . 42˚C, NADA and TRPV1 have overlapping distributions, because low pH, and capsaicin, the active ingredient in chili peppers (5). NADA has been detected in the striatum, cerebellum, hippocam- TRPV1 is highly expressed in the peripheral nervous system, pus, thalamus, brainstem, and dorsal root ganglia (7, 19, 20, 23, specifically in a subset of small-diameter primary sensory neurons 29). Moreover, NADA has been proposed to modulate neuronal in trigeminal nerve and dorsal root ganglia that detect noxious homeostasis by reducing or inducing cation influx via activation of stimuli and in the inferior (nodose) ganglion of the vagus nerve cannabinoid receptors and TRPV1, respectively (1, 30). In addition *Biomedical Sciences Graduate Program, University of California, San Francisco, TLR agonist challenge experiments; E.W. and F.X. performed cecal ligation and San Francisco, CA 94143; †Department of Anesthesia and Perioperative Care, Uni- puncture surgeries; A.T., S.K.L., and E.W. collected and processed plasma samples versity of California, San Francisco, San Francisco, CA 94143; and ‡Division of and performed ELISAs; K.W., A.P., and S.K.L. performed the multiplex experiments; Critical Care Medicine, University of California, San Francisco, San Francisco, and K.W. and S.K.L. performed the ex vivo experiments. M.S. provided input into the CA 94143 design of studies and contributed to the writing of the manuscript. All authors pro- vided input on experimental design. 1J.H. and K.W. are cosenior authors. Address correspondence and reprint requests to Dr. Judith Hellman, Department of ORCID: 0000-0002-1424-0932 (A.P.). Anesthesia, University of California, San Francisco, 500 Parnassus Avenue, Box Received for publication December 22, 2016. Accepted for publication June 13, 0648, San Francisco, CA 94143. E-mail address: [email protected] 2017. The online version of this article contains supplemental material. This work was supported by grants from the Department of Anesthesia and Perioper- Abbreviations used in this article: AEA, anandamide; 2-AG, 2-arachidonoyl glycerol; ative Care, University of California, San Francisco (to J.H.), the International Anes- CB, cannabinoid; CBR, CB receptor; CB R, CBR 1; CB R, CBR 2; CD45.1+, B6. thesia Research Society (to J.H.), National Science Foundation Graduate Research 1 2 SJL-Ptprca mice; CGRP, calcitonin gene–related peptide; CLP, cecal ligation and Fellowship Program Grant 1144247 (to S.K.L.), and the University of California, San puncture; CV, coefficient of variability; FCSB, Flow Cytometry Staining Buffer; Francisco Research Evaluation and Allocation Committee/Research Allocation Pro- LC-MS/MS, liquid chromatography–tandem mass spectrometry; NADA, N-arachi- gram (Huntington Fund; to J.H.). donoyl dopamine; PAI, plasminogen activator inhibitor; TRPV1, transient receptor K.W. and J.H. conceptualized the project; K.W. conceptualized the design of exper- potential vanilloid 1; Trpv12/2, B6.129 3 1-Trpv1tm1Jul/J; WT, wild-type. iments, analyzed data, and contributed to the writing of the manuscript; J.H. super- This article is distributed under The American Association of Immunologists, Inc., vised the project, acquired funding, and analyzed data; S.K.L. designed and Reuse Terms and Conditions for Author Choice articles. performed experiments, including the neuropeptide enzyme immunoassay experi- ments, generated bone marrow chimera mice, performed flow cytometry, and ana- Ó lyzed data. S.K.L. and J.H. wrote the manuscript. S.K.L., F.X., and A.T. conducted Copyright 2017 by The American Association of Immunologists, Inc. 0022-1767/17/$30.00 www.jimmunol.org/cgi/doi/10.4049/jimmunol.1602151 1466 NADA REDUCES INFLAMMATION IN SEPSIS VIA NONMYELOID TRPV1 to its neurologic and behavioral effects, limited studies suggest that Immunoassays and MTT assay NADA has anti-inflammatory effects on nonneuronal cells, such as IL-6, CCL-2, IL-10, and plasminogen activator inhibitor (PAI)-1 levels were astrocytes, leukocytes, and endothelial cells (2, 24, 31–34). quantified in mouse plasma samples by ELISA (R&D Systems, Minne- We previously found that treatment with NADA reduces the acti- apolis, MN and Innovative Research, Novi, MI). Substance P and CGRPa/b vation of cultured endothelial cells by TNF-a, as well as by bacterial levels were quantified in mouse plasma samples by enzyme immunoassay lipopeptides (TLR2 agonists) and LPS (endotoxin, TLR4 agonist) (Enzo Life Sciences, Farmingdale, NY and Cayman Chemicals, Ann Arbor, MI, respectively), and absorbance was read using a FLUOstar OPTIMA (24). Furthermore, our data using pharmacological
Recommended publications
  • Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System

    Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System

    International Journal of Molecular Sciences Review Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System Shenglong Zou and Ujendra Kumar * Faculty of Pharmaceutical Sciences, The University of British Columbia, Vancouver, BC V6T 1Z4, Canada; [email protected] * Correspondence: [email protected]; Tel.: +1-604-827-3660; Fax: +1-604-822-3035 Received: 9 February 2018; Accepted: 11 March 2018; Published: 13 March 2018 Abstract: The biological effects of cannabinoids, the major constituents of the ancient medicinal plant Cannabis sativa (marijuana) are mediated by two members of the G-protein coupled receptor family, cannabinoid receptors 1 (CB1R) and 2. The CB1R is the prominent subtype in the central nervous system (CNS) and has drawn great attention as a potential therapeutic avenue in several pathological conditions, including neuropsychological disorders and neurodegenerative diseases. Furthermore, cannabinoids also modulate signal transduction pathways and exert profound effects at peripheral sites. Although cannabinoids have therapeutic potential, their psychoactive effects have largely limited their use in clinical practice. In this review, we briefly summarized our knowledge of cannabinoids and the endocannabinoid system, focusing on the CB1R and the CNS, with emphasis on recent breakthroughs in the field. We aim to define several potential roles of cannabinoid receptors in the modulation of signaling pathways and in association with several pathophysiological conditions. We believe that the therapeutic significance of cannabinoids is masked by the adverse effects and here alternative strategies are discussed to take therapeutic advantage of cannabinoids. Keywords: cannabinoid; endocannabinoid; receptor; signaling; central nervous system 1. Introduction The plant Cannabis sativa, better known as marijuana, has long been used for medical purpose throughout human history.
  • N-Acyl-Dopamines: Novel Synthetic CB1 Cannabinoid-Receptor Ligands

    N-Acyl-Dopamines: Novel Synthetic CB1 Cannabinoid-Receptor Ligands

    Biochem. J. (2000) 351, 817–824 (Printed in Great Britain) 817 N-acyl-dopamines: novel synthetic CB1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo Tiziana BISOGNO*, Dominique MELCK*, Mikhail Yu. BOBROV†, Natalia M. GRETSKAYA†, Vladimir V. BEZUGLOV†, Luciano DE PETROCELLIS‡ and Vincenzo DI MARZO*1 *Istituto per la Chimica di Molecole di Interesse Biologico, C.N.R., Via Toiano 6, 80072 Arco Felice, Napoli, Italy, †Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, R. A. S., 16/10 Miklukho-Maklaya Str., 117871 Moscow GSP7, Russia, and ‡Istituto di Cibernetica, C.N.R., Via Toiano 6, 80072 Arco Felice, Napoli, Italy We reported previously that synthetic amides of polyunsaturated selectivity for the anandamide transporter over FAAH. AA-DA fatty acids with bioactive amines can result in substances that (0.1–10 µM) did not displace D1 and D2 dopamine-receptor interact with proteins of the endogenous cannabinoid system high-affinity ligands from rat brain membranes, thus suggesting (ECS). Here we synthesized a series of N-acyl-dopamines that this compound has little affinity for these receptors. AA-DA (NADAs) and studied their effects on the anandamide membrane was more potent and efficacious than anandamide as a CB" transporter, the anandamide amidohydrolase (fatty acid amide agonist, as assessed by measuring the stimulatory effect on intra- hydrolase, FAAH) and the two cannabinoid receptor subtypes, cellular Ca#+ mobilization in undifferentiated N18TG2 neuro- CB" and CB#. NADAs competitively inhibited FAAH from blastoma cells. This effect of AA-DA was counteracted by the l µ N18TG2 cells (IC&! 19–100 M), as well as the binding of the CB" antagonist SR141716A.
  • Chapter Four – TRPA1 Channels: Chemical and Temperature Sensitivity

    Chapter Four – TRPA1 Channels: Chemical and Temperature Sensitivity

    CHAPTER FOUR TRPA1 Channels: Chemical and Temperature Sensitivity Willem J. Laursen1,2, Sviatoslav N. Bagriantsev1,* and Elena O. Gracheva1,2,* 1Department of Cellular and Molecular Physiology, Yale University School of Medicine, New Haven, CT, USA 2Program in Cellular Neuroscience, Neurodegeneration and Repair, Yale University School of Medicine, New Haven, CT, USA *Corresponding author: E-mail: [email protected], [email protected] Contents 1. Introduction 90 2. Activation and Regulation of TRPA1 by Chemical Compounds 91 2.1 Chemical activation of TRPA1 by covalent modification 91 2.2 Noncovalent activation of TRPA1 97 2.3 Receptor-operated activation of TRPA1 99 3. Temperature Sensitivity of TRPA1 101 3.1 TRPA1 in mammals 101 3.2 TRPA1 in insects and worms 103 3.3 TRPA1 in fish, birds, reptiles, and amphibians 103 3.4 TRPA1: Molecular mechanism of temperature sensitivity 104 Acknowledgments 107 References 107 Abstract Transient receptor potential ankyrin 1 (TRPA1) is a polymodal excitatory ion channel found in sensory neurons of different organisms, ranging from worms to humans. Since its discovery as an uncharacterized transmembrane protein in human fibroblasts, TRPA1 has become one of the most intensively studied ion channels. Its function has been linked to regulation of heat and cold perception, mechanosensitivity, hearing, inflam- mation, pain, circadian rhythms, chemoreception, and other processes. Some of these proposed functions remain controversial, while others have gathered considerable experimental support. A truly polymodal ion channel, TRPA1 is activated by various stimuli, including electrophilic chemicals, oxygen, temperature, and mechanical force, yet the molecular mechanism of TRPA1 gating remains obscure. In this review, we discuss recent advances in the understanding of TRPA1 physiology, pharmacology, and molecular function.
  • Cannabinoid Receptor and Inflammation

    Cannabinoid Receptor and Inflammation

    Cannabinoid Receptor and Inflammation Newman Osafo1, Oduro Yeboah1, Aaron Antwi1, and George Ainooson1 1Kwame Nkrumah University of Science and Technology September 11, 2020 Abstract The eventual discovery of endogenous cannabinoid receptors CB1 and CB2 and their endogenous ligands has generated interest with regards to finally understanding the endocannabinoid system. Its role in the normal physiology of the body and its implication in pathological states such as cardiovascular diseases, neoplasm, depression and pain have been subjects of scientific interest. In this review the authors focus on the endogenous cannabinoid pathway, the critical role of cannabinoid receptors in signaling and mediation of neurodegeneration and other inflammatory responses as well as its potential as a drug target in the amelioration of some inflammatory conditions. Though the exact role of the endocannabinoid system is not fully understood, the evidence found leans heavily towards a great potential in exploiting both its central and peripheral pathways in disease management. Cannabinoid therapy has already shown great promise in several preclinical and clinical trials. 1.0 Introduction Ethnopharmacological studies have shown the use of Cannabis sativa in traditional medicine for over a thousand years, with its widespread use promoted by its psychotropic effects (McCoy, 2016; Turcotte et al., 2016). The discovery of a receptor within human body, that is selectively activated by cannabinoids suggested the presence of at least one endogenous ligand for this receptor. This is confirmed by the discovery of two endogenously synthesized lipid mediators, 2-arachidonoyl-glycerol and arachidonoylethanolamide, which function as high-affinity ligands for a subfamily of cannabinoid receptors ubiquitously distributed in the central nervous system, known as the CB1 receptors (Turcotte et al., 2016).
  • Pharmacology for PAIN: Prescribing Controlled Substances

    Pharmacology for PAIN: Prescribing Controlled Substances

    The Impact of Pain Pharmacology for PAIN: The National Center for Health Prescribing Controlled Statistics estimates that 32.8% of the U.S. population has persistent pain ~94 million U.S. residents have episodic or Substances persistent pain (1 in every 5 adults) Judith A. Kaufmann, Dr PH, FNP-BC Treatment for chronic pain rarely Robert Morris University results in complete relief and full functional recovery Of patients diagnosed with chronic pain and treated by a PCP, 64 percent report persistent pain two years after treatment initiation US Statistics: The Alarming Impact of Pain Facts Pain ranks low on medical tx priority Americans constitute 4.6% of world’s only 15% of primary care physicians report that they "enjoy" treating patients with chronic pain population-but consume ~ 80% of world’s Dahl et al., and Redford (2002) found that patients opioid supply said they fear dying in pain more than they fear death Americans consume 99% of world supply of hydrocodone Pain over the past 10 years has been designated the 5th vital sign Between 1999 and 2006, the number of people >age 12 using illicit prescription Pain is 3rd leading cause of absence pain relievers doubled from 2.6 to 5.2 from work million 2006 National Survey on Drug Use and Health (NSDUH) Are we the Pushers? Can we be found guilty? Since 1999, opioid analgesic poisonings on 55.7% of users obtained drugs from a death certificates increased 91% friend or relative who had been prescribed the drugs from 1 provider During same period, fatal heroin and cocaine poisonings increased 12.4% and 22.8% 19.1% of users obtained their drug directly respectively from 1 provider In 2008, 36,450 opioid deaths were 1.6% reported doctor shopping reported 3.9% reported purchasing drugs from a CDC, 2011 dealer Male:female ratio = 1.5:1 but death rate for females ia 20x higher than males 1 Is opioid abuse a recent Classifications of Pain phenomenon? Acute V.
  • The Action Mechanism of Daptomycin

    The Action Mechanism of Daptomycin

    The final publication is available at Elsevier via http://dx.doi.org/10.1016/j.bmc.2016.05.052 © 2016. The Action Mechanism of Daptomycin Scott D. Taylor, Michael Palmer Department of Chemistry, University of Waterloo, Waterloo, ON N2L 3G1, Canada Abstract Daptomycin is a lipopeptide antibiotic produced by the soil bacterium Strep- tomyces roseosporus that is clinically used to treat severe infections with Gram- positive bacteria. In this review, we discuss the mode of action of this impor- tant antibiotic. Although daptomycin is structurally related to amphomycin and similar lipopeptides that inhibit peptidoglycan biosynthesis, experimen- tal studies have not produced clear evidence that daptomycin shares their action mechanism. Instead, the best characterized effect of daptomycin is the permeabilization and depolarization of the bacterial cell membrane. This ac- tivity, which can account for daptomycin’s bactericidal effect, correlates with the level of phosphatidylglycerol (PG) in the membrane. Accordingly, reduced synthesis of PG or its increased conversion to lysyl-PG promotes bacterial re- sistance to daptomycin. While other resistance mechanisms suggest that dap- tomycin may indeed directly interfere with cell wall synthesis or cell division, such effects still await direct experimental confirmation. Daptomycin’s com- plex structure and biosynthesis have hampered the analysis of its structure activity relationships. Novel methods of total synthesis, including a recent one that is carried out entirely on a solid phase, will enable a more thorough and systematic exploration of the sequence space. Keywords: calcium-dependent lipopeptide antibiotics, bacterial membranes, membrane potential Email addresses: [email protected] (Scott D. Taylor), [email protected] (Michael Palmer) Preprint submitted to Bioorganic & Medicinal Chemistry May 6, 2016 1.
  • Vancomycin-Lipopeptide Conjugates with High Antimicrobial Activity on Vancomycin-Resistant Enterococci

    Vancomycin-Lipopeptide Conjugates with High Antimicrobial Activity on Vancomycin-Resistant Enterococci

    pharmaceuticals Article Vancomycin-Lipopeptide Conjugates with High Antimicrobial Activity on Vancomycin-Resistant Enterococci 1, 1, 2 3 3 Eric Mühlberg y, Florian Umstätter y, Cornelius Domhan , Tobias Hertlein , Knut Ohlsen , Andreas Krause 1, Christian Kleist 1, Barbro Beijer 1, Stefan Zimmermann 4, Uwe Haberkorn 1,5, Walter Mier 1 and Philipp Uhl 1,* 1 Department of Nuclear Medicine, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany; [email protected] (E.M.); [email protected] (F.U.); [email protected] (A.K.); [email protected] (C.K.); [email protected] (B.B.); [email protected] (U.H.); [email protected] (W.M.) 2 Institute of Pharmacy and Molecular Biotechnology, Heidelberg University, Im Neuenheimer Feld 364, 69120 Heidelberg, Germany; [email protected] 3 Institute for Molecular Infection Biology, University of Würzburg, Josef-Schneider-Straße 2/D15, 97080 Würzburg, Germany; [email protected] (T.H.); [email protected] (K.O.) 4 Department of Medical Microbiology and Hygiene, Heidelberg University Hospital, Im Neuenheimer Feld 324, 69120 Heidelberg Germany; [email protected] 5 Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Centre (DKFZ), Im Neuenheimer Feld 260, 69120 Heidelberg, Germany * Correspondence: [email protected]; Tel.: +49-6221-56-7726 These authors contributed equally. y Received: 23 April 2020; Accepted: 27 May 2020; Published: 29 May 2020 Abstract: Multidrug-resistant bacteria represent one of the most important health care problems worldwide. While there are numerous drugs available for standard therapy, there are only a few compounds capable of serving as a last resort for severe infections.
  • Cell Penetrating Peptides, Novel Vectors for Gene Therapy

    Cell Penetrating Peptides, Novel Vectors for Gene Therapy

    pharmaceutics Review Cell Penetrating Peptides, Novel Vectors for Gene Therapy Rebecca E. Taylor 1 and Maliha Zahid 2,* 1 Mechanical Engineering, Biomedical Engineering and Electrical and Computer Engineering, Carnegie Mellon University, Pittsburgh, PA 15213, USA; [email protected] 2 Department of Developmental Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15201, USA * Correspondence: [email protected]; Tel.: +1-412-692-8893; Fax: +1-412-692-6184 Received: 5 February 2020; Accepted: 1 March 2020; Published: 3 March 2020 Abstract: Cell penetrating peptides (CPPs), also known as protein transduction domains (PTDs), first identified ~25 years ago, are small, 6–30 amino acid long, synthetic, or naturally occurring peptides, able to carry variety of cargoes across the cellular membranes in an intact, functional form. Since their initial description and characterization, the field of cell penetrating peptides as vectors has exploded. The cargoes they can deliver range from other small peptides, full-length proteins, nucleic acids including RNA and DNA, liposomes, nanoparticles, and viral particles as well as radioisotopes and other fluorescent probes for imaging purposes. In this review, we will focus briefly on their history, classification system, and mechanism of transduction followed by a summary of the existing literature on use of CPPs as gene delivery vectors either in the form of modified viruses, plasmid DNA, small interfering RNA, oligonucleotides, full-length genes, DNA origami or peptide nucleic acids. Keywords: cell penetrating peptides; protein transduction domains; gene therapy; small interfering RNA 1. Introduction The plasma membrane of a cell is essential to its identity and survival, but at the same time presents a barrier to intracellular delivery of potentially diagnostic or therapeutic cargoes.
  • Cannabinoids: Novel Molecules with Significant Clinical Utility

    Cannabinoids: Novel Molecules with Significant Clinical Utility

    CANNABINOIDS: NOVEL MOLECULES WITH SIGNIFICANT CLINICAL UTILITY NOEL ROBERT WILLIAMS MD FACOG DIRECTOR OPTIMAL HEALTH ASSOCIATES OKLAHOMA CITY, OKLAHOMA How Did We Get Here? • In November 2012 Tikun Olam, an Israeli medical cannabis facility, announced a new strain of the plant which has only CBD as an active ingredient, and virtually no THC, providing some of the medicinal benefits of cannabis without euphoria. The Researchers said the cannabis plant, enriched with CBD, “can be used for treating diseases like rheumatoid arthritis, colitis, liver inflammation, heart disease and diabetes.” Cannabis CBD like in this article is legally derived from the hemp plant. • CBD is the major non-psychoactive component of Cannabis Sativa (Hemp). Hemp plants are selectively developed and grown to contain high amounts of CBD and very low amounts of the psychoactive component THC found in marijuana. A few CBD oil manufacturers further purify their products to contain high amounts of CBD and no THC. 2014 Farm Bill Terminology • Active Ingredient • Zero THC • Cannabidiol • Isolate • PCR – Phytocannabinoid-Rich • Hemp Oil Extract • “Recommendation” vs. “Prescribed” • Full Spectrum Endocannabinoids (AEA) Phytocannabinoids Full Spectrum & Active Ingredient • CBD – Cannabidiol • A major phytocannabinoid, accounting for as much as 85% of the plant’s extract • CBC – Cannabichromene • Anti-inflammatory & anti-fungal effects have been seen • CBG – Cannabigerol • The parent molecule from which many other cannabinoids are made • CBDV – Cannabidivarin • A homolog of CBD that has been reported to have powerful anti-convulsive effects • CBN – Cannabinol • Sleep & Appetite regulation • Terpenes • Wide spectrum of non-psychoactive molecules that are know to act on neural receptors and neurotransmitters, enhance norepinephrine activity, and potentially increases dopamine activity.
  • Fungal Pathogenesis in Humans the Growing Threat

    Fungal Pathogenesis in Humans the Growing Threat

    Fungal Pathogenesis in Humans The Growing Threat Edited by Fernando Leal Printed Edition of the Special Issue Published in Genes www.mdpi.com/journal/genes Fungal Pathogenesis in Humans Fungal Pathogenesis in Humans The Growing Threat Special Issue Editor Fernando Leal MDPI • Basel • Beijing • Wuhan • Barcelona • Belgrade Special Issue Editor Fernando Leal Instituto de Biolog´ıa Funcional y Genomica/Universidad´ de Salamanca Spain Editorial Office MDPI St. Alban-Anlage 66 4052 Basel, Switzerland This is a reprint of articles from the Special Issue published online in the open access journal Genes (ISSN 2073-4425) from 2018 to 2019 (available at: https://www.mdpi.com/journal/genes/special issues/Fungal Pathogenesis Humans Growing Threat). For citation purposes, cite each article independently as indicated on the article page online and as indicated below: LastName, A.A.; LastName, B.B.; LastName, C.C. Article Title. Journal Name Year, Article Number, Page Range. ISBN 978-3-03897-900-5 (Pbk) ISBN 978-3-03897-901-2 (PDF) Cover image courtesy of Fernando Leal. c 2019 by the authors. Articles in this book are Open Access and distributed under the Creative Commons Attribution (CC BY) license, which allows users to download, copy and build upon published articles, as long as the author and publisher are properly credited, which ensures maximum dissemination and a wider impact of our publications. The book as a whole is distributed by MDPI under the terms and conditions of the Creative Commons license CC BY-NC-ND. Contents About the Special Issue Editor ...................................... vii Fernando Leal Special Issue: Fungal Pathogenesis in Humans: The Growing Threat Reprinted from: Genes 2019, 10, 136, doi:10.3390/genes10020136 ..................
  • “Clipp”Ing on Lipids to Generate Antibacterial Lipopeptides† Cite This: Chem

    “Clipp”Ing on Lipids to Generate Antibacterial Lipopeptides† Cite This: Chem

    Chemical Science View Article Online EDGE ARTICLE View Journal | View Issue “CLipP”ing on lipids to generate antibacterial lipopeptides† Cite this: Chem. Sci., 2020, 11,5759 ac abc d d All publication charges for this article Victor Yim, Iman Kavianinia, Melanie K. Knottenbelt, Scott A. Ferguson, have been paid for by the Royal Society Gregory M. Cook,d Simon Swift, e Aparajita Chakraborty,ab Jane R. Allison, ab of Chemistry Alan J. Cameron,ab Paul W. R. Harris *abc and Margaret A. Brimble *abc We herein report the synthesis and biological and computational evaluation of 12 linear analogues of the Received 30th March 2020 cyclic lipopeptide battacin, enabled by Cysteine Lipidation on a Peptide or Amino Acid (CLipPA) Accepted 20th May 2020 technology. Several of the novel “CLipP”ed lipopeptides exhibited low micromolar MICs and MBCs DOI: 10.1039/d0sc01814g against both Gram-negative and Gram-positive bacteria. The mechanism of action was then simulated rsc.li/chemical-science with the MIC data using computational methods. Introduction a heptapeptide ring and a single amino acid exocyclic tail capped Creative Commons Attribution-NonCommercial 3.0 Unported Licence. by a fatty acid. Battacin 1 is cationic, arising from the ve a,g- Naturally occurring antimicrobial peptides (AMPs) form part of diaminobutyric acid (Dab) residues. The lactam ring is formed the innate immune system and are recognised as potentially between a Dab side chain amine and a Leu carboxyl. Due to its useful therapeutic agents. Due to the unique and non-specic similarity, battacin 1 is postulated to act similarly to polymxyin bactericidal mechanism of action (MOA) of AMPs, it is antibiotics, whereby electrostatic interactions occur with the believed that AMPs have a lower tendency to elicit antibiotic negatively charged lipid A head groups of lipopolysaccharides resistance than conventional antibiotics.1–3 Lipopeptides, (LPS) on the surface of the bacterial outer membrane (OM), a subclass of AMPs, have emerged as a new class of antibiotics, leading to accumulation at the bacterial surface.
  • Transient Receptor Potential Cation Channel, Subfamily C, Member 5 (TRPC5) Is a Cold-Transducer in the Peripheral Nervous System

    Transient Receptor Potential Cation Channel, Subfamily C, Member 5 (TRPC5) Is a Cold-Transducer in the Peripheral Nervous System

    Transient receptor potential cation channel, subfamily C, member 5 (TRPC5) is a cold-transducer in the peripheral nervous system Katharina Zimmermanna,b,1,2, Jochen K. Lennerza,c,d,1,3, Alexander Heina,1,4, Andrea S. Linke, J. Stefan Kaczmareka,b, Markus Dellinga, Serdar Uysala, John D. Pfeiferc, Antonio Riccioa, and David E. Claphama,b,f,5 Departments of aCardiology, Manton Center for Orphan Disease, and bNeurobiology, Harvard Medical School, Boston, MA 02115; cDepartment of Pathology and Immunology, Washington University, St. Louis, MO, 63110; dDepartment of Pathology, Massachusetts General Hospital/Harvard Medical School, Boston, MA, 02116; eDepartment of Physiology and Pathophysiology, University Erlangen, 91054 Erlangen, Germany; and fHoward Hughes Medical Institute, Harvard Medical School, Children’s Hospital Boston, Boston, MA 02115 Contributed by David E. Clapham, September 20, 2011 (sent for review August 9, 2011) Detection and adaptation to cold temperature is crucial to survival. affected perforce by temperature, even if driven solely by con- Cold sensing in the innocuous range of cold (>10–15 °C) in the ventional NaV and KV channels—but high Q10 channels are likely mammalian peripheral nervous system is thought to rely primarily suspects in encoding temperature changes. Although TRPM8 on transient receptor potential (TRP) ion channels, most notably (a menthol receptor) is generally considered the primary cold – the menthol receptor, TRPM8. Here we report that TRP cation sensor for innocuous cold (11 13), and TRPA1 participates in channel, subfamily C member 5 (TRPC5), but not TRPC1/TRPC5 het- noxious cold sensing (9, 10) (14), many cold-sensitive neurons eromeric channels, are highly cold sensitive in the temperature lack TRPM8 as well as TRPA1 (15).